title: Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension.
abstract: OBJECTIVE
  To investigate whether dorzolamide alters corneal hydration control in patients with glaucoma or ocular hypertension.
  
  
  METHODS
  Pachymetry, tonometry, and endothelial cell density were measured by a masked observer in 19 subjects with bilateral glaucoma or ocular hypertension. They were treated with 2% dorzolamide in one eye, and with saline in the other, before wearing contact lenses under patched eyes. Corneal thickness, measured each 30 minutes up to 4.5 hours after contact lens removal, enabled estimation of percentage recovery per hour and time for 95% of corneal thickness recovery for both eyes. Seven patients repeated this test after 1 year of dorzolamide use, and their results were compared with those of the preceding year.
  
  
  RESULTS
  After induction of hypoxic corneal edema, there was no significant difference between paired corneas in swelling levels (60.0+/-11.8 and 59.8+/-12.9 microm) (P = .94), time to 95% recovery (440.6+/-255.8 and 445.4+/-186.7 minutes) (P = .93), and percentage recovery per hour (38.1%+/-10.9% and 36.1%+/-9.6%) (P = .40). Subjects followed up after 1 year of dorzolamide use did not differ significantly in values of endothelial cell density, percentage recovery per hour, or time to 95% recovery from those obtained a year before. One subject developed persistent corneal edema after his stress test in the eye treated with dorzolamide.
  
  
  CONCLUSIONS
  There is no significant difference in the recovery from induced corneal edema after either a short-term or 1-year use of dorzolamide in patients with glaucoma or ocular hypertension with a normal corneal endothelium. One patient had persistent corneal edema after the stress test was performed on the dorzolamide-treated eye.
authors.affiliation: Guy-Bernier Research Center, Ophthalmology Research Unit, Hôpital Maisonneuve-Rosemont, School of Optometry, Université de Montréal, Québec, Canada.
authors.forename: C J
authors.initials: CJ
authors.lastname: Giasson
authors.forename: T Q
authors.initials: TQ
authors.lastname: Nguyen
authors.forename: H M
authors.initials: HM
authors.lastname: Boisjoly
authors.forename: M R
authors.initials: MR
authors.lastname: Lesk
authors.forename: M
authors.initials: M
authors.lastname: Amyot
authors.forename: M
authors.initials: M
authors.lastname: Charest
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D002452:Cell Count; D003261:Contact Lenses / Q000009:adverse effects; D003315:Cornea / Q000187:drug effects / Q000503:physiopathology*; D015715:Corneal Edema / Q000209:etiology / Q000503:physiopathology*; D004311:Double-Blind Method; D004728:Endothelium, Corneal / Q000187:drug effects; D005260:Female; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D013449:Sulfonamides / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D014065:Tonometry, Ocular
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide